Role of hematological biomarkers in predicting oncological outcomes of definitive chemoradiation in locally advanced vulvar carcinoma
Background: The systemic inflammatory response triggered by the carcinogenic process induces significant changes in a wide range of hematological biomarkers, impacting their levels, functions, and overall roles in the body’s physiological and pathological processes. Objective: To evaluate the value of pre-treatment hematological parameters in the prediction of clinical and radiological responses of locally advanced vulvar cancer to definitive chemoradiation. Methods: We retrospectively reviewed the medical records of patients treated at the King Hussein Cancer Center receiving definitive chemoradiation for pathologically confirmed locally advanced vulvar carcinoma. Response of the primary disease to treatment was classified as complete response (CR) if there was no clinically- or radiologically-confirmed residual disease at 12 weeks after completion of chemoradiation. Univariate analyses on complete response, progression-free survival (PFS), and overall survival (OS) were performed using clinical factors and pre-treatment hematological parameters. Results: A total of 30 patients were included, with a median age of 57.5 years and a median follow-up of 21 months. Of these, 24 patients (80%) achieved CR. Disease progression occurred in 11 patients (36.7%) during the follow-up period, and 9 (30%) died. Kaplan–Meier analysis demonstrated that only the neutrophil–to–lymphocyte ratio (NLR) (p = 0.007) and basophil–to–lymphocyte ratio (BLR) (p = 0.05) were predictive of OS. Conversely, PFS was significantly associated with white blood cell count (p = 0.042) and BLR (p = 0.004). Receiver operating characteristic (ROC) analysis indicated that NLR and BLR had significant predictive power for survival at the following cutoffs: 3.4 and 0.035, respectively. When categorized by ROC values, BLR was significantly associated with response to treatment (p = 0.026). Moreover, both NLR and BLR were significantly associated with OS and PFS. Conclusion: Pre-treatment NLR and BLR may be useful predictive markers for clinical and radiological response, as well as for oncological outcomes in locally advanced vulvar cancer treated with definitive chemoradiation.
- Alkatout I, Schubert M, Garbrecht N, et al. Vulvar cancer: Epidemiology, clinical presentation, and management options. Int J Womens Health. 2015;7:305-313. doi: 10.2147/IJWH.S68979
- Mahner S, Jueckstock J, Hilpert F, et al. Adjuvant therapy in lymph node-positive vulvar cancer: The AGO-CaRE-1 study. J Natl Cancer Inst. 2015;107(3):dju426. doi: 10.1093/jnci/dju426
- Gill BS, Bernard ME, Lin JF, et al. Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis. Gynecol Oncol. 2015;137(3):365-372. doi: 10.1016/j.ygyno.2015.03.056
- Rao YJ, Chin RI, Hui C, et al. Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database. Gynecol Oncol. 2017;146(3): 572-579. doi: 10.1016/j.ygyno.2017.06.022
- Bucchi L, Pizzato M, Rosso S, Ferretti S. New insights into the epidemiology of vulvar cancer: Systematic literature review for an update of incidence and risk factors. Cancers (Basel). 2022;14(2):389. doi: 10.3390/cancers14020389
- Fatalska A, Rusetska N, Bakuła-Zalewska E, et al. Inflammatory proteins HMGA2 and PRTN3 as drivers of vulvar squamous cell carcinoma progression. Cancers (Basel). 2020;13(1):27. doi: 10.3390/cancers13010027
- Bartl T, Bekos C, Postl M, et al. The systemic immune-inflammation index (SII) is an independent prognostic parameter of survival in patients with invasive vulvar cancer. J Gynecol Oncol. 2020;32(1):e1. doi: 10.3802/jgo.2021.32.e1
- Mleko M, Pitynski K, Pluta E, et al. Role of systemic inflammatory reaction in female genital organ malignancies - state of the art. Cancer Manag Res. 2021;13:5491-5508. doi: 10.2147/CMAR.S312828
- Aksoy E, Karakurt Z, Gungor S, et al. Neutrophil to lymphocyte ratio is a better indicator of COPD exacerbation severity in neutrophilic endotypes than eosinophilic endotypes. Int J Chron Obstruct Pulmon Dis. 2018;13:2721-2730. doi: 10.2147/COPD.S170353
- Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899. doi: 10.1016/j.cell.2010.01.025
- Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-998. doi: 10.1038/ni1102-991
- Zhou Q, Hong L, Zuo MZ, He Z. Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: Evidence from 4,910 patients. Oncotarget. 2017;8(40):68938-68949. doi: 10.18632/oncotarget.20196
- Ertas IE, Gungorduk K, Akman L, et al. Can preoperative neutrophil: lymphocyte and platelet: lymphocyte ratios be used as predictive markers for lymph node metastasis in squamous cell carcinoma of the vulva? Eur J Obstet Gynecol Reprod Biol. 2013;171(1):138-142. doi: 10.1016/j.ejogrb.2013.08.023
- Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383-5391. doi: 10.1158/0008-5472.CAN-08-3845
- Winarto H, Habiburrahman M, Anggraeni TD, et al. The utility of pre-treatment inflammation markers as associative factors to the adverse outcomes of vulvar cancer: A study on staging, nodal involvement, and metastasis models. J Clin Med. 2022;12(1):96. doi: 10.3390/jcm12010096
- Lavie O, Comerci G, Daras V, Bolger BS, Lopes A, Monaghan JM. Thrombocytosis in women with vulvar carcinoma. Gynecol Oncol. 1999;72(1):82-86. doi: 10.1006/gyno.1998.5225
- Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366: 610-618. doi: 10.1056/NEJMoa1110352
- Lee JW, Seol KH. Pretreatment neutrophil-to-lymphocyte ratio combined with platelet-to-lymphocyte ratio as a predictor of survival outcomes after definitive concurrent chemoradiotherapy for cervical cancer. J Clin Med. 2021;10(10):2199. doi: 10.3390/jcm10102199
- Zhang CL, Jiang XC, Li Y, et al. Independent predictive value of blood inflammatory composite markers in ovarian cancer: Recent clinical evidence and perspective focusing on NLR and PLR. J Ovarian Res. 2023;16(1):36. doi: 10.1186/s13048-023-01116-2
- Li YX, Chang JY, He MY, et al. Neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) predict clinical outcome in patients with stage IIB cervical cancer. J Oncol. 2021;2021:2939162. doi: 10.1155/2021/2939162
- Prabawa IPY, Bhargah A, Liwang F, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pac J Cancer Prev. 2019;20(3):863-868. doi: 10.31557/APJCP.2019.20.3.863
- Ferro M, Di Lorenzo G, Vartolomei MD, et al. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette- Guérin after transurethral resection of the bladder tumor. World J Urol. 2020;38(1):143-150. doi: 10.1007/s00345-019-02754-2
- De Monte L, Wörmann S, Brunetto E, et al. Basophil recruitment into tumor-draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic cancer patients. Cancer Res. 2016;76(7):1792-1803. doi: 10.1158/0008-5472.CAN-15-1801-T
- Hadadi A, Smith KE, Wan L, et al. Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. Urol Oncol. 2022;40(6):271.e9-e18. doi: 10.1016/j.urolonc.2022.03.016
- Yang Z, Zhang Z, Lin F, et al. Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases. APMIS. 2017;125(10):863-871. doi: 10.1111/apm.12722
- Rosner S, Kwong E, Shoushtari AN, et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med. 2018;7(3):690-697. doi: 10.1002/cam4.1356
- Wei Y, Zhang X, Wang G, et al. The impacts of pretreatment circulating eosinophils and basophils on prognosis of stage I-III colorectal cancer. Asia Pac J Clin Oncol. 2018;14(5):e243-e251. doi: 10.1111/ajco.12871
- Johann S, Klaeser B, Krause T, Mueller MD. Comparison of outcome and recurrence-free survival after sentinel lymph node biopsy and lymphadenectomy in vulvar cancer. Gynecol Oncol. 2008;110(3):324-328. doi: 10.1016/j.ygyno.2008.04.004
- Meelapkij P, Suprasert P, Baisai O. Treatment outcomes of patients with squamous cell carcinoma of the vulva: The largest series from a tertiary care hospital. Obstet Gynecol Int. 2018;2018:4723167. doi: 10.1155/2018/4723167
- Natesan D, Susko M, Havrilesky L, Chino J. Definitive chemoradiotherapy for vulvar cancer. Int J Gynecol Cancer. 2016;26(9):1699-1705. doi: 10.1097/IGC.0000000000000811
- Abuhijla F, Salah S, Al-Hussaini M, et al. Factors influencing the use of adaptive radiation therapy in vulvar carcinoma. Rep Pract Oncol Radiother. 2020;25(5):709-713. doi: 10.1016/j.rpor.2020.06.005
- Arians N, Prigge ES, Nachtigall T, et al. Overexpression of p16INK4a serves as prognostic marker in squamous cell vulvar cancer patients treated with radiotherapy irrespective of HPV-status. Front Oncol. 2019;9:891. doi: 10.3389/fonc.2019.00891
- Proctor L, Hoang L, Moore J, et al. Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2020;30(1):100-106. doi: 10.1136/ijgc-2019-000793